Literature DB >> 22992326

Resection with total caudate lobectomy confers survival benefit in hilar cholangiocarcinoma of Bismuth type III and IV.

Q-B Cheng1, B Yi, J-H Wang, X-Q Jiang, X-J Luo, C Liu, R-Z Ran, P-N Yan, B-H Zhang.   

Abstract

PURPOSE: To identify prognostic predictors for overall survival of patients with hilar cholangiocarcinoma of Bismuth type III and IV (HCBT34), and to determine survival benefit and safety of total caudate lobectomy (TCL) in a Chinese centre.
METHODS: From January 2001 to December 2010, 171 patients with the diagnosis of HCBT34, who underwent a potentially curative resection, were included in this study. Cox proportional hazards regression models were used to determine the association between possible prognostic variables and survival time. Curative resectability rate, morbidity and mortality were investigated also.
RESULTS: Resection with TCL was significantly associated with more opportunity to achieve curative resection (p < 0.01), did not accompany with more morbidity (p = 0.39) and mortality (p = 0.67). Cox regression analysis demonstrated positive resection margins [Relative Risk (RR) 3.6, 95% CI 3.5-3.7], not well differentiation (RR 2.9, 95% CI 2.7-3.1), higher preoperative serum peak CA19-9 level (RR 1.6, 95% CI 1.5-1.7) and regional lymph nodes involvement (RR 1.5, 95% CI 1.4-1.6) as independent adverse prognostic variables.
CONCLUSIONS: Resection with TCL offers a long-term survival opportunity for HCBT34, with high curative resectability rates and an acceptable safety profile.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22992326     DOI: 10.1016/j.ejso.2012.08.009

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  28 in total

1.  Principles of surgical resection in hilar cholangiocarcinoma.

Authors:  Emilio Ramos
Journal:  World J Gastrointest Oncol       Date:  2013-07-15

2.  Defining Early Recurrence of Hilar Cholangiocarcinoma After Curative-intent Surgery: A Multi-institutional Study from the US Extrahepatic Biliary Malignancy Consortium.

Authors:  Xu-Feng Zhang; Eliza W Beal; Jeffery Chakedis; Qinyu Chen; Yi Lv; Cecilia G Ethun; Ahmed Salem; Sharon M Weber; Thuy Tran; George Poultsides; Andre Y Son; Ioannis Hatzaras; Linda Jin; Ryan C Fields; Stefan Buettner; Charles Scoggins; Robert C G Martin; Chelsea A Isom; Kamron Idrees; Harveshp D Mogal; Perry Shen; Shishir K Maithel; Carl R Schmidt; Timothy M Pawlik
Journal:  World J Surg       Date:  2018-09       Impact factor: 3.352

3.  Hilar cholangiocarcinoma: expert consensus statement.

Authors:  John C Mansour; Thomas A Aloia; Christopher H Crane; Julie K Heimbach; Masato Nagino; Jean-Nicolas Vauthey
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

Review 4.  The Surgical Management of Klatskin Tumours: Has Anything Changed in the Last Decade?

Authors:  Neil Bhardwaj; Giuseppe Garcea; Ashley R Dennison; Guy J Maddern
Journal:  World J Surg       Date:  2015-11       Impact factor: 3.352

5.  Transhepatic Direct Approach to the "Limit of the Division of the Hepatic Ducts" Leads to a High R0 Resection Rate in Perihilar Cholangiocarcinoma.

Authors:  Takehiro Noji; Kimitaka Tanaka; Aya Matsui; Yoshitsugu Nakanishi; Toshimichi Asano; Toru Nakamura; Takahiro Tsuchikawa; Keisuke Okamura; Satoshi Hirano
Journal:  J Gastrointest Surg       Date:  2021-01-05       Impact factor: 3.452

Review 6.  Perihilar cholangiocarcinoma: Current therapy.

Authors:  Wei Zhang; Lu-Nan Yan
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

7.  Applied anatomy of small branches of the portal vein in transverse groove of hepatic hilum.

Authors:  Pei-ning Yan; Wei-feng Tan; Xin-wei Yang; Chuan-sen Zhang; Xiao-qing Jiang
Journal:  Surg Radiol Anat       Date:  2014-05-03       Impact factor: 1.246

Review 8.  Curative-intent surgery for hilar cholangiocarcinoma: prognostic factors for clinical decision making.

Authors:  Irinel Popescu; Traian Dumitrascu
Journal:  Langenbecks Arch Surg       Date:  2014-05-20       Impact factor: 3.445

9.  Hepatic Artery Resection for Bismuth Type III and IV Hilar Cholangiocarcinoma: Is Reconstruction Always Required?

Authors:  Hai-Jie Hu; Yan-Wen Jin; Rong-Xing Zhou; Anuj Shrestha; Wen-Jie Ma; Qin Yang; Jun-Ke Wang; Fei Liu; Nan-Sheng Cheng; Fu-Yu Li
Journal:  J Gastrointest Surg       Date:  2018-03-06       Impact factor: 3.452

Review 10.  Multimodal treatment strategies for advanced hilar cholangiocarcinoma.

Authors:  Matthew J Weiss; David Cosgrove; Joseph M Herman; Neda Rastegar; Ihab Kamel; Timothy M Pawlik
Journal:  Langenbecks Arch Surg       Date:  2014-06-25       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.